We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Read MoreHide Full Article
Medtronic plc (MDT - Free Report) recently won the FDA’s Investigational Device Exemption (IDE) for the SLATE (Stereotactic Laser Ablation for Temporal Lobe Epilepsy) trial, which will evaluate this medical technology giant’s Visualase MRI-Guided Laser Ablation technology. Notably, the Visualase technology helps perform minimally invasive neurosurgery.
The IDE has been granted for expansion of the 510 (k)-approved Visualase technology's indication to include patients suffering from drug resistant mesial temporal lobe epilepsy (MTLE). The results from the pivotal SLATE clinical trial will substantially reflect the efficacy of Visualase technology in treating drug-resistant MTLE patients.
The SLATE study aims at enrolling 120 adult patients suffering from drug-resistant MTLE, who will be treated at selected epilepsy centers across the U.S. Post 1 year of undergoing the Visualase procedure, a follow-up will be done on these patients to estimate their quality of life, adverse events, freedom from seizures and neurophysiological outcomes.
Drug-resistant MTLE & Treatment
Epilepsy is a common neurological disorder that currently affects 3 million U.S. citizens, of which at least one-third are estimated to have developed drug-resistance. Since drug therapy is the most common form of treatment for epilepsy patients, it becomes difficult to cure those who have developed a resistance for the same.
Meanwhile, surgery has of late emerged as an effective way of treating drug-resistant epilepsy; however, the procedure is not very commonly used. Evidently, of the 30% of patients whose seizures cannot be controlled with drugs, approximately one third (more than 100,000 in the U.S.) is potential candidates for epilepsy surgery.
Management at Medtronic believes that on release of favorable results from the SLATE trial, physicians will be able to effectively recommend their patients to undergo the Visualase technology treatment.
Our Take
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, we believe that the aforementioned FDA go-ahead will bring in a new, effective device in the neurosurgery market (provided the results are favorable).
In its last reported fourth quarter of 2016, Medtronic’s Surgical Technologies business witnessed revenue growth of 5%, partially driven by high-single-digit growth in Neurosurgery. We expect positive results from the SLATE trial to boost this business division apart from expanding the company’s footprint in the billion-dollar neurosurgical market.
Zacks Rank
Medtronic currently carries a Zacks Rank #3 (Hold). Better-ranked medical stocks are Baxter International Inc. (BAX - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . While Baxter sports a Zacks Rank #1 (Strong Buy), ICU Medical and LeMaitre carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Medtronic plc (MDT - Free Report) recently won the FDA’s Investigational Device Exemption (IDE) for the SLATE (Stereotactic Laser Ablation for Temporal Lobe Epilepsy) trial, which will evaluate this medical technology giant’s Visualase MRI-Guided Laser Ablation technology. Notably, the Visualase technology helps perform minimally invasive neurosurgery.
The IDE has been granted for expansion of the 510 (k)-approved Visualase technology's indication to include patients suffering from drug resistant mesial temporal lobe epilepsy (MTLE). The results from the pivotal SLATE clinical trial will substantially reflect the efficacy of Visualase technology in treating drug-resistant MTLE patients.
The SLATE study aims at enrolling 120 adult patients suffering from drug-resistant MTLE, who will be treated at selected epilepsy centers across the U.S. Post 1 year of undergoing the Visualase procedure, a follow-up will be done on these patients to estimate their quality of life, adverse events, freedom from seizures and neurophysiological outcomes.
Drug-resistant MTLE & Treatment
Epilepsy is a common neurological disorder that currently affects 3 million U.S. citizens, of which at least one-third are estimated to have developed drug-resistance. Since drug therapy is the most common form of treatment for epilepsy patients, it becomes difficult to cure those who have developed a resistance for the same.
Meanwhile, surgery has of late emerged as an effective way of treating drug-resistant epilepsy; however, the procedure is not very commonly used. Evidently, of the 30% of patients whose seizures cannot be controlled with drugs, approximately one third (more than 100,000 in the U.S.) is potential candidates for epilepsy surgery.
Management at Medtronic believes that on release of favorable results from the SLATE trial, physicians will be able to effectively recommend their patients to undergo the Visualase technology treatment.
Our Take
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, we believe that the aforementioned FDA go-ahead will bring in a new, effective device in the neurosurgery market (provided the results are favorable).
In its last reported fourth quarter of 2016, Medtronic’s Surgical Technologies business witnessed revenue growth of 5%, partially driven by high-single-digit growth in Neurosurgery. We expect positive results from the SLATE trial to boost this business division apart from expanding the company’s footprint in the billion-dollar neurosurgical market.
Zacks Rank
Medtronic currently carries a Zacks Rank #3 (Hold). Better-ranked medical stocks are Baxter International Inc. (BAX - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . While Baxter sports a Zacks Rank #1 (Strong Buy), ICU Medical and LeMaitre carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>